Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, patients with treatment-refractory alopecia areata who received oral ritlecitinib 50 mg daily experienced significant hair regrowth, with 52.6% achieving complete scalp regrowth and improved Severity of Alopecia Tool scores, indicating its potential effectiveness in real-world settings.

This case report presents the first instance of a pediatric alopecia areata patient switching from baricitinib to ritlecitinib, demonstrating favorable clinical outcomes, suggesting a potential new treatment pathway for children with severe cases of this condition.

In this study, topical phenylephrine significantly reduced hair shedding and increased the force needed to pluck hair in women undergoing cosmetic procedures, suggesting its potential utility for traction alopecia.

This case report describes a 7-year-old female from the Middle East with monilethrix, highlighting the disease's rarity in this population, characterized by brittle, sparse hair and keratosis pilaris.

This commentary discusses the declining status of scalp reduction in hair restoration practice and reports no new clinical findings.

In this study, real-world data of 31 patients using ritlecitinib for severe alopecia areata showed that 51% achieved significant hair regrowth after one year, with no serious adverse events reported, emphasizing the importance of considering treatment duration for response.

In this prospective study, ritlecitinib effectively reduced hair loss in patients with severe alopecia areata, with 43.3% of participants achieving a 20 or lower SALT score by week 24, and showed a good midterm safety profile.

This study examines the depiction of a soldier with an atypical hairstyle resembling alopecia in an Isenmann painting, possibly reflecting medical conditions like tinea capitis or alopecia areata to emphasize the soldier's moral degradation, though artists historically mixed medical conditions for stylistic purposes.

Ritlecitinib effectively treats alopecia areata and is well-tolerated.

In this study, newly diagnosed women with mycosis fungoides or Sézary syndrome and those with alopecia experienced significantly poorer health-related quality of life.

This study found that the oral JAK inhibitors ritlecitinib and brepocitinib were effective in maintaining hair regrowth in alopecia areata with continuous use, though efficacy decreased after withdrawal.

This study found that some patients with alopecia areata who did not respond to ritlecitinib treatment by Week 24 achieved a positive response with continued therapy by Week 48, with tolerable side effects.

This study reports that ritlecitinib was prescribed to a diverse group of patients, including adolescents and adults with and without prior treatment for Alopecia Areata, in the first three months after FDA approval, potentially expanding care options for this condition.

This report describes a rare case of papular atrichia in a 4-year-old girl, highlighting the absence of effective treatment to stimulate hair growth for this condition.

In this case study, an 18-year-old woman's triangular alopecic patch diagnosed as temporal triangular alopecia was considered non-progressive and had no impact on her quality of life, so no treatment was initiated.

According to this study, Ireland’s current eligibility criteria for financial assistance on hair replacement products exclude many individuals with alopecia, such as children with non-chemotherapy-induced alopecia, and expanding support could align the country with more inclusive international policies.

This study found that psychopathological reactions, particularly cognitive impairments such as impaired concentration, are prevalent among patients with diffuse alopecia, with variations in prevalence linked to the genesis of alopecia, notably higher in mixed-type compared to metabolic-type alopecia.

This study resulted in a draft version of the Patient‐Reported Impact of Dermatological Diseases measure, PRIDD, which includes 27 items refined from patient consensus and is now undergoing psychometric testing.

This review provides insights and guidelines for clinicians and patients on assessing the risks and benefits of ritlecitinib for adolescents with alopecia areata, emphasizing shared decision-making and management strategies.

Ritlecitinib may help treat alopecia areata by protecting hair follicles.

In this study, researchers found that cutaneous hyperpigmentation is a primary dermatological manifestation in patients with Graves' disease, with certain treatments like carbimazole and propranolol being statistically associated with skin symptoms.

This study focused on baricitinib's effect on patients with severe alopecia areata, highlighting its efficacy for hair regrowth and its potential to improve health-related quality of life and psychological symptoms, as seen in two phase 3 trials.

Ritlecitinib is effective and safe for treating alopecia areata, promoting significant hair regrowth.

This case report describes a patient with trichothiodystrophy presenting with autism, mental retardation, and seizures, characterized by distinct hair abnormalities under microscopy.

This case report found that topical bimatoprost usage in a female Hispanic patient with open-angle glaucoma was associated with hypertrichosis and increased pigmentation of vellus hairs on the malar region.

In this study, researchers examined Baricitinib's role as a treatment for Alopecia Areata, contrasting it with conventional therapies, and found that while effective, Baricitinib may cause adverse reactions depending on individual patient health histories.

This study reviews literature showing that trichotillomania significantly reduces quality of life and emphasizes that effective treatment requires an interdisciplinary approach involving dermatology and psychiatry to address its psychiatric component.

This study found that ritlecitinib, taken daily, led to scalp, eyebrow, and eyelash hair regrowth in patients aged 12 and older with severe and very severe alopecia areata over a 24-month period.